ABCL — AbCellera Biologics Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1703057 ·
Last close
$10.61
Market Cap
$3.44B
52W High
$12.15
52W Low
$4.98
ADV30
8,392,289
Next earnings
2026-11-05
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 4,050,000 -58,923,000 -55,427,000 1,307,575,000 120,065,000 411,555,000
Mar 2026 8,315,000 -53,180,000 -43,165,000 1,307,112,000 77,063,000 369,029,000
Dec 2025 44,853,000 -25,266,000 -8,945,000 1,356,950,000 128,513,000 390,046,000
Sep 2025 8,955,000 -73,549,000 -57,119,000 1,355,992,000 83,159,000 391,954,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-94,937,000
Investing CF
$97,886,000
Financing CF
$25,072,000
CapEx
$-24,734,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.63
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-128,074,000
Inventory
$7,578,000
Receivables
$95,425,000
ST Investments
$420,039,000
EBIT TTM
$-210,918,000
Pretax Income TTM
$-196,769,000
Interest Exp TTM
$42,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$66,170,000
EBITDA
$-199,960,000
Free Cash Flow
$-46,431,124
Enterprise Value
$3,066,354,688
Total Cash
$540,104,000
Total Debt
$135,616,992
Shares Out
324,047,363
Trailing EPS
$-0.54
Book Value
$2.92
ROE
-17.3%
ROA
-10.4%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 75,128,000 -203,213,000 -146,412,000 1,356,950,000 390,046,000 -131,295,000
Dec 2024 28,833,000 -301,146,000 -162,857,000 1,360,553,000 304,469,000 -108,556,000
Dec 2023 38,025,000 -223,052,000 -146,398,000 1,488,094,000 335,776,000 -43,877,000
Dec 2022 485,424,000 227,065,000 158,519,000 1,540,907,000 307,630,000 277,360,000
Dec 2021

TTM Snapshot

Revenues TTM
$107,890,000
NetIncome TTM
$-24,483,000
OpCashFlow TTM
$0
Assets (Latest)
$1,360,553,000
Forward EPS
$-0.71

Max Pain — expiry 2026-09-18

max pain strike: $9.00 · spot: $10.61 · call oi: 13,252 · put oi: 5,611
Expected Move to 2026-09-18: ±$1.90 (17.91%) — implied range $8.71$12.51 · ATM straddle on $11.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GPCR Structure Therapeutics Inc. $3.49B $49.01
QURE uniQure N.V. $3.29B $47.46
OGN Organon & Co. $3.61B $13.75
KNSA Kiniksa Pharmaceuticals International, plc $3.68B $79.38
NAMS NewAmsterdam Pharma Co N.V. $3.21B $26.85

News headlines (Yahoo Finance, 1h cache)

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
2026-08-14 22:53 · Yahoo
AbCellera (ABCL) Q2 2026 Earnings Call Transcript
2026-08-13 00:31 · Yahoo
AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?
2026-08-12 07:10 · Yahoo
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal
2026-08-12 06:14 · Yahoo
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results
2026-08-11 21:11 · Yahoo
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
2026-08-11 02:31 · Yahoo
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook
2026-08-10 21:40 · Yahoo
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
2026-08-13 04:05 · Yahoo
AbCellera Stock Jumps 33% on a Positive Menopause Trial
2026-08-10 16:05 · Yahoo
AbCellera shares surge 22% after ABCL635 delivers positive Phase 2 results
2026-08-10 12:45 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-08-24 17:21:48 2026-08-24 Hayden Michael R Dir P - Purchase 10.64 53613 570442
2026-08-18 14:45:24 2026-08-18 Montalbano John S. Dir P - Purchase 11.03 10000 110300